Consensus estimates for CalciMedica’s Q2 2026 report reflect zero revenue and a projected EPS loss of -$0.33, while the current share price of $0.75 remains significantly below the average analyst target of $10.54.
Investors are primarily focused on the company’s cash position and critical FDA feedback regarding the pivotal program design for Auxora in acute pancreatitis (AP) following positive earlier clinical data.
Although CalciMedica reported a surprise profit in Q1 due to non-cash fair value adjustments, the underlying burn rate required a $49 million financing round in late June to extend the runway. This capital is vital as the company seeks to recover from the earlier setback of discontinuing its KOURAGE trial in acute kidney injury.